半夏-陈皮药对基于CYP17A1基因改善多囊卵巢综合征的机制研究
该研究结合PCOS大鼠模型与DHT诱导的KGN细胞模型,运用网络分析、代谢组学及分子生物学验证,发现半夏-陈皮药对可改善PCOS表型,其主要成分柚皮素与川陈皮素通过激活以CYP17A1为核心的类固醇生物合成通路发挥作用。
要点
- 半夏-陈皮药对可改善PCOS大鼠体重、动情周期及性激素水平。
- 柚皮素与川陈皮素上调CYP17A1、CYP19A1,下调AKR1C3、HSD17B1。
- 机制涉及激活以CYP17A1为中心的类固醇生物合成通路。
核心结论
- 半夏-陈皮药对通过激活以CYP17A1为核心的类固醇生物合成通路改善PCOS。
研究设计与样本
- 采用高脂饮食联合来曲唑诱导的PCOS大鼠模型与DHT诱导的人颗粒细胞KGN模型进行体内外实验。
- 结合吸收成分分析、生物信息学、代谢组学与网络分析筛选核心靶点,并用RT-qPCR和Western blot验证。
主要发现
- 半夏-陈皮药对在体内显著改善PCOS大鼠体重增加、动情周期紊乱并恢复正常性激素水平。
- 上调类固醇生物合成相关代谢物cortolone与progesterone,CYP19A1、AKR1C3、HSD17B1为CYP17A1的关键调节因子。
- 主要成分柚皮素与川陈皮素增加CYP17A1和CYP19A1蛋白表达,降低AKR1C3和HSD17B1表达。
临床怎么用
- 提示半夏-陈皮药对可能用于痰湿证PCOS患者的临床管理,其机制与CYP17A1介导的类固醇合成相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: As a typical Traditional Chinese Medicine (TCM) couplet medicine, Arum Ternatum Thunb. (Pinellia ternata (Thunb.) Makino, known as Banxia in Chinese) and Citrus Reticulata (pericarps of Citrus reticulata Blanco, known as Chenpi in Chinese) has been widely used in clinical practice for their properties of drying dampness, resolving phlegm, relieving oppression and masses. According to the TCM theories, the imbalance in fluid metabolism could lead to the accumulation of the excess dampness and phlegm, resulting in the pathological phenotype as 'damp-phlegm syndrome'. It can further lead to polycystic ovary syndrome (PCOS) when this accumulation of the excess fluid presents in uterus, affecting women's fertility and endocrine function. Recent studies have indicated that Banxia-Chenpi herbal pair (BXCP) exhibits significant therapeutic effects on damp-phlegm syndrome, yet the precise mechanisms underlying its anti-PCOS actions remain to be fully elucidated. AIM OF THE STUDY: The objective was to investigate the signaling pathway involved in steroid biosynthesis, particularly the cytochrome P450 family 17, subfamily A, member 1 (CYP17A1), and to evaluate the effects and mechanisms of BXCP in ameliorating PCOS through both in vivo and in vitro experiments. MATERIALS AND METHODS: A systematic evaluation was conducted to assess BXCP's effects on serum biochemical indicators and ovarian tissue pathology in a PCOS rat model (induced by high-fat diet + letrozole) and a DHT-induced human granulosa cells (KGN) model. Core targets were screened using absorbed components analysis, bioinformatics, metabolomics, and network analysis. RT-qPCR and Western blot techniques were employed to confirm the expression of CYP17A1 and related signaling molecule expression during BXCP's amelioration of PCOS, both in vivo and in vitro. RESULTS: BXCP significantly ameliorated PCOS in vivo by mitigating weight gain, regulating estrus cycles, and normalizing sex hormone levels in rats. It upregulated metabolites related to steroid biosynthesis, including cortolone and progesterone, with CYP19A1, AKR1C3, and HSD17B1 as key regulators of CYP17A1. The main BXCP components, Naringenin and Nobiletin, increased CYP17A1 and CYP19A1 protein expression while decreased AKR1C3 and HSD17B1. CONCLUSION: In conclusion, BXCP ameliorates PCOS by activating the CYP17A1-centered steroid biosynthesis pathway. These findings provide new insights into BXCP's clinical potentials in the management of patients with PCOS, highlighting the importance of TCM in modern medicine.
引用
- Shen C, Li H, Xiao M, et al. Study on the mechanism of the Chinese herbal pair Banxia-Chenpi in ameliorating polycystic ovary syndrome based on the CYP17A1 gene. J Ethnopharmacol. 2025. PMID: 39961422. doi:10.1016/j.jep.2025.119503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。